MAP2K7 and breast carcinoma: Interestingly in PIK3CA mutant breast cancer cells, activation of ERK has been demonstrated and appears to be largely independent of RAS.39 The activation of ERK1/2 in this setting appears to instead be mediated by the RAC1/CRAF/MEK/ERK pathway.